Advertisement
BIO vs DHR
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Danaher (DHR) Stock Comparison
Key Takeaways
- Bio-Rad Laboratories (BIO) focuses on life science research and clinical diagnostics tools, while Danaher (DHR) operates a broader portfolio spanning bioprocessing, diagnostics, and environmental solutions.
- In recent market activity, DHR has delivered stronger year-to-date total returns compared to BIO, which has faced headwinds from academic end-market softness.
- BIO reported first-quarter 2026 net sales of $592.1 million with updated non-GAAP revenue guidance reflecting potential contraction on a currency-neutral basis.
- DHR posted first-quarter 2026 earnings per share above consensus estimates and maintains an upcoming second-quarter earnings release scheduled for July 21, 2026.
- Both companies operate in the life sciences sector, exposing them to similar macroeconomic factors such as research funding trends and global supply-chain conditions, yet DHR’s scale provides greater diversification.
- Market sentiment has shown relative stability for DHR amid positive earnings momentum, while BIO has experienced more pronounced price volatility in recent weeks.
Introduction
Bio-Rad Laboratories (BIO) and Danaher (DHR) represent two established players in the life sciences and diagnostics space, making them natural candidates for comparison among institutional and retail investors seeking exposure to healthcare innovation and laboratory instrumentation. Traders monitoring sector rotation, earnings cycles, and relative valuation metrics may find this analysis useful for assessing positioning within a diversified portfolio. The comparison highlights differences in business scale, end-market exposure, and recent price behavior without implying directional forecasts. Both stocks trade on the New York Stock Exchange and are subject to the same broad equity-market influences, including interest-rate expectations and biotechnology funding trends.
BIO Overview and Recent Performance
Bio-Rad Laboratories (BIO) develops and manufactures products for life science research and clinical diagnostics, including reagents, instruments, and software used in academic, pharmaceutical, and hospital laboratories. In recent market activity, the stock has traded within a range influenced by first-quarter 2026 results that showed reported sales growth of 1.1 percent year-over-year to $592.1 million, although currency-neutral sales declined 4.2 percent amid softer academic demand and geopolitical factors. Non-GAAP operating margins remained steady near 10–12 percent in the updated guidance. Price action in recent weeks has reflected these mixed fundamentals, with the shares closing at $283.86 on July 8, 2026, resulting in a year-to-date total return of 6.31 percent. Sentiment has been tempered by the company’s emphasis on cost optimization and share repurchases during the period.
DHR Overview and Recent Performance
Danaher (DHR) provides a diversified suite of life sciences, diagnostics, and environmental solutions through operating companies focused on bioprocessing, medical diagnostics, and water quality testing. Recent market activity has been supported by first-quarter 2026 results that featured adjusted earnings per share of $2.06, exceeding analyst expectations, and strength in bioprocessing. The company is scheduled to release second-quarter 2026 earnings on July 21, 2026. As of July 8, 2026, the stock closed at $190.77, delivering a year-to-date total return of 16.31 percent. Broader investor attention has centered on integration progress following prior acquisitions and the company’s ability to sustain growth across multiple end markets despite macroeconomic uncertainty.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a much larger pool of hundreds of bots that collectively trade thousands of different tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this trending section. Available bots span a wide range of trading styles, strategies, timeframes, and performance statistics, allowing users to review metrics such as win rates, average trade duration, and drawdown profiles. The platform’s transparent presentation of these variables enables traders to evaluate suitability for specific market environments. Review the full selection of Trending AI Robots to explore current options.
Head-to-Head Comparison
Bio-Rad Laboratories (BIO) maintains a narrower focus on research and diagnostics instrumentation, resulting in greater sensitivity to academic and government laboratory budgets. Danaher (DHR) benefits from broader diversification across bioprocessing and multiple industrial end markets, which can moderate earnings volatility. Recent momentum favors DHR on a year-to-date basis, while BIO has shown more limited price appreciation amid segment-specific pressures. Risk factors for BIO include currency fluctuations and slower recovery in research spending; DHR faces integration and acquisition-related execution risks alongside broader healthcare policy exposure. Sector sentiment remains constructive for both, yet DHR’s larger market capitalization and analyst coverage provide a different liquidity and visibility profile compared with the smaller BIO.
Tickeron AI Verdict
Based on observable factors including stronger year-to-date total returns, earnings-beat consistency, and upcoming catalyst visibility, Tickeron’s AI models currently assign a higher probabilistic weighting to Danaher (DHR) relative to Bio-Rad Laboratories (BIO) in trend-consistency and stability assessments. This positioning reflects measurable differences in recent performance metrics and sector positioning rather than any forward projection.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a StrongBuy and DHR is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 4 TA indicator(s) are bullish while DHR’s TA Score has 6 bullish TA indicator(s).
- BIO’s TA Score: 4 bullish, 4 bearish.
- DHR’s TA Score: 6 bullish, 4 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а +0.82% price change this week, while DHR (@Medical Specialties) price change was +3.38% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +7.62%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -16.57%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.19%. For the same industry, the average monthly price growth was +9.26%, and the average quarterly price growth was +1.11%.
Reported Earning Dates
BIO is expected to report earnings on Jul 30, 2026.
DHR is expected to report earnings on Jul 21, 2026.
Industries' Descriptions
@Medical/Nursing Services (+7.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.19% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | DHR | BIO / DHR | |
| Capitalization | 8.02B | 142B | 6% |
| EBITDA | 440M | 7.08B | 6% |
| Gain YTD | -1.786 | -12.195 | 15% |
| P/E Ratio | 49.51 | 38.79 | 128% |
| Revenue | 2.59B | 24.8B | 10% |
| Total Cash | 1.57B | N/A | - |
| Total Debt | 1.38B | 18.5B | 7% |
BIO | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 80 | |
PRICE GROWTH RATING 1..100 | 52 | 52 | |
P/E GROWTH RATING 1..100 | 10 | 49 | |
SEASONALITY SCORE 1..100 | 90 | 18 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (10) in the Medical Specialties industry is significantly better than the same rating for BIO (83). This means that DHR’s stock grew significantly faster than BIO’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BIO (100). This means that DHR’s stock grew similarly to BIO’s over the last 12 months.
DHR's SMR Rating (80) in the Medical Specialties industry is in the same range as BIO (90). This means that DHR’s stock grew similarly to BIO’s over the last 12 months.
DHR's Price Growth Rating (52) in the Medical Specialties industry is in the same range as BIO (52). This means that DHR’s stock grew similarly to BIO’s over the last 12 months.
BIO's P/E Growth Rating (10) in the Medical Specialties industry is somewhat better than the same rating for DHR (49). This means that BIO’s stock grew somewhat faster than DHR’s over the last 12 months.
| BIO | DHR | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 50% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 59% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 66% | 1 day ago 53% |
| Advances ODDS (%) | 18 days ago 66% | 1 day ago 54% |
| Declines ODDS (%) | 6 days ago 68% | 14 days ago 61% |
| BollingerBands ODDS (%) | 1 day ago 65% | 1 day ago 56% |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 49% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.